IONIS PHARMACEUTICALS INC(IONS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

IONIS PHARMACEUTICALS INC (IONS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IONS at 23.4/100 on a 32-signal composite quality model, placing it at rank #2,720 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (8.2) and profitability (9.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IONIS PHARMACEUTICALS INC reports quarterly revenue of $267.9M, net income of $-114.6M, an operating margin of -38.2%. Top institutional holders of IONS by reported 13-F value include FMR, Capital World Investors, BlackRock, based on the most recent SEC filings. IONS trades on the Nasdaq exchange and files with the SEC under CIK 874015. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IONS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IONIS PHARMACEUTICALS INC directly from SEC EDGAR.